Global Age-Related Macular Degeneration (AMD) Market Report 2019: Covers Historic & Future Industry Data for the Period 2016-2026 - ResearchAndMarkets.com

The "Global Age-Related Macular Degeneration Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

The Global Age-Related Macular Degeneration Market is expected to reach $15,882.7 million by 2026 growing at a CAGR of 9.5% from 2018 to 2026.

Some of the factors such as increasing geriatric population and rising predominance of age-related macular degeneration are fuelling the market growth. However, increasing use of off label drugs and availability of off label therapies are restraining the market growth.

Based on the drug, lucentis segment has witnessed significant growth. Lucentis is used to treat the "wet form" of age-related macular degeneration. Lucentis is also used to treat swelling in the retina caused by diabetes or by a blockage in the blood vessels.

The key vendors mentioned are Valeant Pharmaceuticals International, Inc., Stemcells Inc., Santen Pharmaceuticals, Regeneron Pharmaceuticals, Pfizer, Inc., Ophthotech Corporation, Novartis Ag, Neurotech Pharmaceuticals, Inc., Kubota Pharmaceutical Holdings Co. Ltd, GlaxoSmithKline Plc, F. Hoffmann-La Roche, Bayer Healthcare, Alimera Sciences, Inc., Adverum Biotechnologies, Inc., and Acucela.

Key Questions Answered in this Report

• How this market evolved since the year 2016
• Market size estimations, forecasts and CAGR for all the segments presented in the scope
• Key Market Developments and financials of the key players
• Opportunity Analysis for the new entrants
• SWOT Analysis of the key players
• Fastest growing markets analyzed during the forecast period

Key Topics Covered

1 Market Synopsis

2 Research Outline

3 Market Dynamics

3.1 Drivers

3.2 Restraints

4 Market Environment

4.1 Bargaining power of suppliers

4.2 Bargaining power of buyers

4.3 Threat of substitutes

4.4 Threat of new entrants

4.5 Competitive rivalry

5 Global Age-Related Macular Degeneration Market, By Drug

5.1 Introduction

5.2 Visudyne

5.3 Lucentis

5.4 Eylea

5.5 Avastin

5.6 Other Drugs

6 Global Age-Related Macular Degeneration Market, By Type

6.1 Introduction

6.2 Dry

6.3 Wet

7 Global Age-Related Macular Degeneration Market, By Stages

7.1 Introduction

7.2 Intermediate

7.3 Early-Stage

7.4 Late Stage

8 Global Age-Related Macular Degeneration Market, By Age group

8.1 Introduction

8.2 Above 75 years

8.3 Above 60 years

8.4 Above 40 years

9 Global Age-Related Macular Degeneration Market, By Route of Administration

9.1 Introduction

9.2 Intravitreal

9.3 Intravenous

10 Global Age-Related Macular Degeneration Market, By Mode of Treatment

10.1 Introduction

10.2 Surgery

10.3 Medication

10.4 Diagnosis

10.5 Devices

11 Global Age-Related Macular Degeneration Market, By Application

11.1 Introduction

11.2 Woman

11.3 Men

12 Global Age-Related Macular Degeneration Market, By End User

12.1 Introduction

12.2 Hospital & Clinics

12.3 Diagnostic Centers

12.4 Biotechnology Companies and Pharmaceuticals

12.5 Academic Research Institutes

13 Global Age-Related Macular Degeneration Market, By Geography

13.1 Introduction

13.2 North America

13.3 Europe

13.4 Asia-Pacific

13.5 South America

13.6 Middle East & Africa

14 Strategic Benchmarking

15 Vendors Landscape

15.1 Valeant Pharmaceuticals International, Inc.

15.2 Stemcells Inc.

15.3 Santen Pharmaceuticals

15.4 Regeneron Pharmaceuticals

15.5 Pfizer, Inc.

15.6 Ophthotech Corporation

15.7 Novartis AG

15.8 Neurotech Pharmaceuticals, Inc.

15.9 Kubota Pharmaceutical Holdings Co. Ltd.

15.10 Glaxosmithkline PLC

15.11 F. Hoffmann-La Roche

15.12 Bayer Healthcare

15.13 Alimera Sciences, Inc.

15.14 Adverum Biotechnologies, Inc.

15.15 Acucela

For more information about this report visit https://www.researchandmarkets.com/r/cvhmxs

View source version on businesswire.com: https://www.businesswire.com/news/home/20191120005813/en/